CELL INTELLIGENCE · 肿瘤细胞治疗研究

利用多尺度机制模型定量表征同种异体抗 CD20 嵌合抗原受体 (CAR) Vδ1 γδ T 细胞的固有与适应性药理学

Quantitative Characterization of Innate and Adaptive Pharmacology of Allogeneic anti-CD20 Chimeric Antigen Receptor (CAR) Vδ1 γδ T cells using Multisc

非常规 T 细胞的原位编程

In situ programming of unconventional T cells.

用于癌症过继性细胞治疗的细胞类型定制水凝胶

Cell-Type-Tailored Hydrogels for Adoptive Cell Therapy in Cancer.

模块化 γδ TCR-T 平台：结合 KRAS pMHC 靶向与可重复给药 mRNA 衔接器重定向

A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection.

原发性皮肤γδ T 细胞淋巴瘤的临床异质性：一项 20 年单中心经验

Clinical heterogeneity of primary cutaneous γδ T-cell lymphoma: a 20-year single-institution experience.

PCGDTCL 似乎表现出比以往认识到的更广泛的临床和治疗异质性。部分患者的持久缓解提示，治疗反应性可能在整个疾病谱中有所不同。

肿瘤细胞治疗的进展与前景：从 T 细胞到干细胞的探索

Advances and prospects in cell therapy for cancer: explorations from T cells to stem cells.

用于癌症免疫治疗的异体 T 细胞平台的工程化策略

Engineering Strategies for Allogeneic T Cell-Based Platforms in Cancer Immunotherapy.

从 T 细胞衔接器到下一代免疫细胞衔接器用于癌症免疫治疗

From T cell engagers to next-generation immune cell engagers for cancer immunotherapy.

利用先进制造与基因工程改造 γδ T 细胞用于肿瘤免疫治疗

Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering.

CAR-γδ T 细胞：可编程先天免疫哨兵的新范式及其在癌症及其他疾病中的系统性应用

CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond.